SEC Form 4 · accession 0001232524-17-000061
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen L. Smith
Officer — Global Head of R&D and CMO
Period of report
Mar 2, 2017
Accepted (ET)
Mar 6, 2017 · 6:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Mar 2, 2017 | A | 7,500 | $0.00 | A | 21,168 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F2 | $136.18 | Mar 2, 2017 | A | 902 | A | — | Mar 1, 2027 | Ordinary Shares | 902 | 902 | D |
| Non-Qualified Stock Option (right to buy)F2 | $136.18 | Mar 2, 2017 | A | 17,848 | A | — | Mar 1, 2027 | Ordinary Shares | 17,848 | 17,848 | D |
Explanation of responses
- F1These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2017, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
- F2These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.